{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-035971","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.913247+00:00","generated_at":"2026-05-15T08:21:14.556036+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protara reports 68% six-month CR rate in TARA-002 trial; triggers warrant exercise period","bullets":["Six-month complete response (CR) rate of 68.0% in 25 BCG-unresponsive NMIBC patients in Phase 2 ADVANCED-2 trial.","CR rate is consistent with the 68.2% announced on February 24, 2026, and meaningfully above 41.9% threshold.","Condition met for fixing termination date of April 2024 common stock warrants; exercisable at $5.25 through June 29, 2026.","Results from open-label trial; further updates may be required for regulatory discussions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-035971","json":"https://secwatch.observer/filing/0001213900-26-035971.json","markdown":"https://secwatch.observer/filing/0001213900-26-035971.md","text":"https://secwatch.observer/filing/0001213900-26-035971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026035971/0001213900-26-035971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026035971/ea0283949-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:21:14.556036+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}